Cancer clinical trials in the region Occitanie

396 currently recruiting clinical trials
Region Occitanie

Phase 3 Lung cancer #NCT07361497 #2025-523576-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
ALK EGFR
8 recruiting sites
Bristol-Myers Squibb
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06476184 #2023-508260-30-01
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Other epithelial ovarian cancer
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
36 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3 Multiple myeloma #NCT07518186 #2025-523815-12-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Monoclonal antibodies Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Janssen
Phase 3 Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06937905
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lung cancer #NCT06937905
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Prostate cancer #NCT07225946 #2025-522713-29-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
Janssen
Phase 3 Breast cancer #NCT06380751
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRCA 1/2 PALB2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Acute leukemia #NCT06652438 #2024-512733-32-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
11 recruiting sites
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Lymphoma Brain tumors / Central nervous system tumors #NCT07104032 #2025-523389-26-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive Targeted therapy Other targeted therapy
2 recruiting sites
Ono Pharmaceutical Co. Ltd.
Phase 3 Breast cancer #NCT07205822 #2025-521904-23-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
5 recruiting sites
AstraZeneca